A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 636 participants.

Also called NCT03861052

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 636 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03861052
Other papers using this trial's data
  • Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial The lancet. Diabetes & endocrinology, 2022-09 DOI, PubMed 35914543 PubMed links an erratum for this paper. Erratum: PMID 41109321

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03861052. Randomized; double masking; primary purpose treatment. Start 2019-05-07 (actual); primary completion 2021-03-10 (actual). Results posted on 2022-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
Acronym
SURPASS J-mono
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Dulaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03861052
Content hash
f16ed8401fdfbdde7cc888f7278a53b018a60f6b7e3203c14b09f3ee34c2ae3f